110627-20-8

Basic information

• Product Name: 1H-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl 2-(4-benzyl-1-piperazinyl)ethyl ester
• CAS NO: 110627-20-8
• Molecular Weight: 560.093
• Mol File: 110627-20-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1H-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl 2-(4-benzyl-1-piperazinyl)ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl 2-(4-benzyl-1-piperazinyl)ethyl ester(110627-20-8)
• EPA Substance Registry System: 1H-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl 2-(4-benzyl-1-piperazinyl)ethyl ester(110627-20-8)

Safety Data

• Hazardous Substances Data: 110627-20-8(Hazardous Substances Data)

Upstream product

• 3221-20-3 1-benzyl-4-(2-hydroxyethyl)piperazine 
• 53-86-1 [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid 

Downstream Products

• 97460-20-3 1H-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl 2-<4-(3-hydroxypropyl)-1-piperazinyl>ethyl ester 
• 110627-21-9 [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid 2-piperazin-1-yl-ethyl ester 

Relevant articles and documents

Pharmacokinetics and metabolism of [14C]-proglumetacin after oral administration in the rat.

The pharmacokinetics and metabolism of 1H-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl 2-[4-[3-[[4-(benzoylamino)-5-(dipropylamino)-1, 5-dioxopentyl]oxy]propyl]-1-piperazinyl]ethyl ester (+/-) (proglumetacin, CR 604), 14C-labelled in position C-2 of the indolic moiety, was studied in male and female rats after oral administration. The radioactivity is slowly absorbed from the gastrointestinal tract and reaches the peak in plasma 6 h after administration. Afterwards the radioactivity is eliminated from plasma according to a bi-exponential equation, with an initial elimination rate having a t1/2 of 4.5 h and a terminal elimination rate having a t1/2 of 16 h. The elimination rate is probably dependent on the slow absorption rate (flip-flop system) and on an entero-hepatic recirculation of the radioactivity. The radioactivity is excreted with the feces (60.8%) and with the urines (33.5%). No radioactivity is eliminated with the expired air. About 13% of the fecal radioactivity is represented by proglumetacin. This fraction or radioactivity (ca. 8% of the administered) represents probably the non-absorbed amount of substance. The parent proglumetacin is not found in blood, urine and organs. Conversely several indolic metabolites are found, with a predomination of indometacin. Proglumetacin is therefore a pro-drug of indometacin and of other indolic metabolites, which are responsible for the antiinflammatory activity of proglumetacin. The radioactivity is distributed in all tissues. The maximum radioactivity is found in liver and kidneys, however, always in a smaller concentration than in plasma. No "deep compartment" was found.